XML 87 R25.htm IDEA: XBRL DOCUMENT
v3.22.0.1

MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2021
Novartis Institutes for BioMedical Research, Inc. |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues recognized under agreement | Revenues recognized under the agreement were as follows (in thousands):
| Year Ended December 31,
| 2021 |  | 2020 |  | 2019 |  |  |
Revenue related to Novartis agreement: |  |  |  |  |  |  |  |
Recognition of upfront license fee | $ | 29,945 |  |  | $ | 4,143 |  |  | $ | — |  |  |  |
Research services | 7,999 |  |  | 1,109 |  |  | — |  |  |  |
Total | $ | 37,944 |  |  | $ | 5,252 |  |  | $ | — |  |  |  |
Biogen MA, Inc. |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues recognized under agreement | Revenues recognized under the agreement were as follows (in thousands):
| Year Ended December 31,
| 2021 |  | 2020 |  | 2019 |  |  |
Revenue related to Biogen agreement: |  |  |  |  |  |  |  |
Recognition of license and stand-ready fee | $ | 29,224 |  |  | $ | 21,356 |  |  | $ | — |  |  |  |
Research services | 13,076 |  |  | 6,545 |  |  | — |  |  |  |
Total | $ | 42,300 |  |  | $ | 27,901 |  |  | $ | — |  |  |  |
Kite Pharma, Inc. |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues recognized under agreement | Revenues recognized under the agreement were as follows (in thousands):
| Year Ended December 31,
| 2021 |  | 2020 |  | 2019 |  |  |
Revenue related to Kite agreement: |  |  |  |  |  |  |  |
Recognition of license and stand-ready fee | $ | 24,977 |  |  | $ | 25,046 |  |  | $ | 24,977 |  |  |  |
Research services | 476 |  |  | 3,562 |  |  | 9,373 |  |  |  |
Total | $ | 25,453 |  |  | $ | 28,608 |  |  | $ | 34,350 |  |  |  |
Pfizer, Giroctocogene Fitelparvovec |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues recognized under agreement | Revenues recognized under the agreement were as follows (in thousands):
| Year Ended December 31,
| 2021 |  | 2020 |  | 2019 |  |
Revenue related to Pfizer giroctocogene fitelparvovec agreement: |  |  |  |  |  |  |
Recognition of upfront fee and research services | $ | — |  |  | $ | 3,111 |  |  | $ | 15,697 |  |  |
Milestone achievement | — |  |  | 31,338 |  |  | 23,662 |  |  |
Total | $ | — |  |  | $ | 34,449 |  |  | $ | 39,359 |  |  |
Pfizer C9ORF72 |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues recognized under agreement | Revenues recognized under the agreement were as follows (in thousands):
| Year Ended December 31,
| 2021 |  | 2020 |  | 2019 |  |
Revenue related to Pfizer C9ORF72 agreement: |  |  |  |  |  |  |
Recognition of upfront fee | $ | — |  |  | $ | 7,985 |  |  | $ | 1,827 |  |  |
Milestone achievement | — |  |  | 5,000 |  |  | — |  |  |
Total | $ | — |  |  | $ | 12,985 |  |  | $ | 1,827 |  |  |
Sanofi S.A. |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues recognized under agreement | Revenues recognized under the agreement were as follows (in thousands):
| Year Ended December 31,
| 2021 |  | 2020 |  | 2019
Revenue related to Sanofi agreement: |  |  |  |  |
Recognition of upfront fee | $ | 34 |  |  | $ | 298 |  |  | $ | 3,494 |
Research services | 3,057 |  |  | 4,823 |  |  | 6,367 |
Milestone achievement | 23 |  |  | 201 |  |  | 12,819 |
Total | $ | 3,114 |  |  | $ | 5,322 |  |  | $ | 22,680 |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_PfizerGiroctocogeneFitelparvovecMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_SanofiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |